Special Episode: Understanding Fremanezumab's Expanded Indication in Pediatric Migraine

Patricia Pozo-Rosich, MD, PhD

A special episode of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

In this special episode, "Understanding Fremanezumab's Expanded Indication in Pediatric Migraine," Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d’Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy; Teva) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393)–the study that led to its expanded indication–Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations.

For more of NeurologyLive's coverage of fremanezumab's expanded indication in pediatric migraine, head here: FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine

EPISODE BREAKDOWN

• 1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care
• 5:00 – Major clinical insights and takeaways from phase 3 SPACE trial
• 8:00 – Neurology News Minute
• 10:20 – Challenges in pediatric migraine trials and addressing high placebo responses
• 13:20 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCE
1. FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine. News release. Teva Pharmaceuticals. August 6, 2025. Accessed September 12, 2025. https://www.tevapharm.com/news-and-media/latest-news/fda-approves-expanded-indication-for-ajovy-fremanezumab-vfrm-the-first-anti-cgrp-preventive-treatment/